Weathering the reform storm: The Inflation Reduction Act’s changes to Medicare and other healthcare markets
Key components and stakeholder implications of drug pricing and other healthcare-related changes in the Inflation Reduction Act
On Aug. 16, President Biden signed the Inflation Reduction Act into law. The act contains healthcare reforms, tax changes, and environmental policy provisions. It also affects several layers of the U.S. healthcare ecosystem with major implications for the Medicare Advantage and Medicare Part D programs. This article focuses on the relevant changes to Medicare, discussing the following:
- Key healthcare provisions of the act
- Potential implications to stakeholders within the healthcare and pharmaceutical sectors
- Next steps and a timetable of changes in the coming years
Explore more tags from this article
About the Author(s)
Weathering the reform storm: The Inflation Reduction Act’s changes to Medicare and other healthcare markets
The Inflation Reduction Act will have countless implications for all industry stakeholders and will alter the Medicare landscape in 2023 and beyond.